Baird served as a joint bookrunner in this transaction
AboutExact Sciences Corporation (“Exact Sciences” or the “Company”) (Nasdaq: EXAS) recently completed a follow-on offering of 6,325,000 shares of its common stock at a price of $9.75 per share, generating gross proceeds of approximately $61.7 million. The Company intends to use the net proceeds from this offering for general corporate and working capital purposes, including for product development and in furtherance of the Company’s efforts to obtain FDA clearance of its sDNA colorectal cancer screening product and product commercialization activities.
Exact Sciences is a molecular diagnostics company focused on colorectal cancer. The Company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. Stool-based DNA technology is included in the colorectal cancer screening guidelines of the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer.
For additional information about this transaction, please contact:
- August 2012
- Exact Sciences Corporation
- Target Location
- North America